Citadel Advisors
CTOR

Citadel Advisors’s Citius Oncology CTOR Stock Holding History

Citadel Advisors’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,661
Closed -$35.9K – 14410
2025
Q3 		$35.9K Buy
+17,661
New +$38.3K ﹤0.01% 12335
2025
Q1 		– Sell
-22,699
Closed -$26.1K – 15813
2024
Q4 		$26.1K Buy
+22,699
New +$25.5K ﹤0.01% 12994

Other funds holding CTOR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's CTOR Position: Q4 2025 in Review

Citadel Advisors sold out of Citius Oncology (CTOR) in Q4 2025, closing a stake of 17,661 shares — an estimated $35.9K sold.

Citadel Advisors first reported a position in CTOR in Q4 2024 and held it in 2 quarters. The position peaked at $35.9K in Q3 2025. 18 funds tracked by Wall St. Rank hold CTOR as of Q4 2025.

  • Citadel Advisors reported no remaining Citius Oncology position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 17,661 Citius Oncology shares in Q4 2025, an estimated $35.9K.
  • Citadel Advisors first reported a position in Citius Oncology in Q4 2024 and held it in 2 quarters.
  • Citadel Advisors's Citius Oncology position peaked at $35.9K in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Citius Oncology as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.